This review is a “Pro-Con” discussion about the optimal fluid volume in critically ill patients in the intensive care unit (ICU). This article argues that fluids should be aggressively managed in critically ill patients.
Liver failure can occur in patients with or without underlying chronic liver disease (mainly cirrhosis) and is, respectively, termed acute on chronic liver failure or acute liver failure (ALF). In both cases, it is associated with...
Effects of levosimendan on mortality in patients with septic shock: systematic review with meta-analysis and trial sequential analysis.
Several studies have investigated a survival benefit for levosimendan treatment in patients with septic shock.
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
Cardiogenic shock (CS) and low cardiac output syndrome (LCOS) as complications of acute myocardial infarction (AMI), heart failure (HF) or cardiac surgery are life-threatening conditions.
Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients.
Effective resuscitation with human albumin solutions is achieved with less fluid than with crystalloid solutions. However, the role of albumin in today's critical care unit is also linked to its multiple pharmacological effects.
Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis.
Cardiac shock is the leading cause of death in patients with acute myocardial infarction.
Patterns of intravenous fluid resuscitation use in adult intensive care patients between 2007 and 2014: An international cross-sectional study
In 2007, the Saline versus Albumin Fluid Evaluation-Translation of Research Into Practice Study (SAFE-TRIPS) reported that...
Goal-directed therapy has been used for severe sepsis and septic shock in the intensive care unit.
After a single-center trial and observational studies suggesting that early, goal-directed therapy (EGDT) reduced mortality from septicshock, three multicenter trials (ProCESS, ARISE, and ProMISe) showed no benefit.
Fluid administration is a key intervention in hemodynamic resuscitation. Timely expansion (or restoration) of plasma volume may prevent tissue hypoxia and help to preserve organ function.